This narrative review synthesizes clinical and experimental evidence on how asymmetric dimethylarginine (ADMA),symmetric dimethylarginine (SDMA), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP) collectively drive early vascular aging and subclinical atherosclerosis. Rather than acting as redundant markers, these molecules govern two distinct yet mutually reinforcing pathways: the enzymatic uncoupling of nitric oxide production and chronic low-grade vascular inflammation. While elevated ADMA correlates independently with early structural wall thickening and coronary calcification, SDMA primarily reflects systemic vascular stress intertwined with renal filtration capacity.Simultaneously, systemic inflammation mediated by IL-6 and hsCRP degrades functional elasticity and accelerates plaque vulnerability.
Arteries do not all age at the same speed. Two 55-year-olds with identical cholesterol and blood pressure can carry arteries that behave like 45 or 70. Researchers call the fast track “early vascular aging” and the slow track “supernormal” aging. The problem is that standard risk calculators, built on cholesterol, blood pressure, smoking and diabetes, often miss who is on which track. Plenty of people labeled low or intermediate risk already have silent plaque.
This review asks whether a handful of blood tests could close that gap. The candidates fall into two camps.
The first camp concerns nitric oxide, the gas that keeps artery linings relaxed and healthy. ADMA, a molecule left over when cells break down methylated proteins, directly blocks the enzyme that makes nitric oxide. When ADMA builds up, that enzyme can misfire and generate damaging free radicals instead. SDMA, a close chemical cousin, works more indirectly by competing with arginine, the raw material for nitric oxide, at the cell’s entry gates.
The second camp is inflammation. IL-6 is a signaling molecule that activates blood vessel linings and recruits immune cells. It also tells the liver to make CRP, the protein measured by the familiar hsCRP test.
The evidence is uneven. ADMA most often turns up alongside thicker carotid artery walls and more coronary calcium. A pooled analysis of over 6,000 people found a modest link with carotid thickness, strongest in kidney disease. Yet the details wobble. In the Framingham study, ADMA tracked thickening at the carotid fork, where plaques form, but not in the straight segment below it. In a large German population study, ADMA showed no link to either carotid measure at all.
SDMA is cleared almost entirely by the kidneys, so high levels may simply reflect declining kidney function. Still, in the Dallas Heart Study and the German cohort, SDMA stayed linked to coronary calcium and carotid thickness even after accounting for kidney function.
For inflammation, genetics makes the strongest case. People born with variants that dampen IL-6 signaling have fewer heart attacks, which suggests causation rather than coincidence. But in the large US MESA cohort, IL-6 stopped predicting new coronary calcium once standard risk factors and statin use were considered.
hsCRP carries the most practical weight. In the Women’s Health Study, women in the top fifth of hsCRP had about 70 percent higher risk of cardiovascular events over 30 years than those in the bottom fifth. In a Chinese cohort of over 25,000 people, hsCRP above 3 mg/L went with faster arterial stiffening over about four and a half years. A Dutch analysis suggested inflammation may drive stiffening more than wall thickening, though it explained only a sliver of age-related change.
One small Greek trial offers a glimpse of modifiability. Six months of intensive diet and exercise coaching lowered ADMA and improved carotid stiffness and wall thickness in people with mild hypertension, and the more inflammatory the diet, the higher the ADMA.
The authors argue the four markers are complementary rather than interchangeable. That is plausible, but untested. Nobody has yet shown that adding them to a standard risk score changes who gets correctly flagged.
Actionable Insights
The evidence demonstrates that protecting long-term arterial youth requires two practical interventions: maintaining cellular nitric oxide bioavailability and aggressively suppressing systemic inflammation.
First, dietary adjustments produce measurable structural benefits. Clinical trial data cited in the review reveal that adopting an intensive lifestyle intervention consisting of an anti-inflammatory diet and aerobic exercise over six months drove a significant decline in asymmetric dimethylarginine. This biochemical reduction directly correlated with reduced arterial stiffness and decreased carotid wall thickness. For each one-unit decrease in the dietary inflammatory index score,circulating dimethylarginine concentrations declined predictably, verifying that dietary quality directly impacts endothelial enzymatic function.
Second, tracking high-sensitivity C-reactive protein (HS-CRP) provides a functional gauge of arterial stiffness. Prospective cohort data tracking over 25,000 adults indicate that maintaining baseline levels below 1 milligram per liter preserves arterial elasticity. Individuals with concentrations exceeding 3 milligrams per liter experience an additional stiffening rate of more than 40 centimeters per second over four to five years compared to those with low inflammation, an acceleration in mechanical vascular aging equivalent to several additional years of physical deterioration. In women followed for 30 years, the top fifth of hsCRP carried about 1.7 times the event risk of the bottom fifth, a small-to-moderate effect. Retest if a result looks high, since a cold or injury can spike it temporarily.
Third, preserving renal filtration capacity prevents symmetric dimethylarginine accumulation. Maintaining optimal glycemic control, sustaining insulin sensitivity, and engaging in habitual zone-2 aerobic conditioning prevent the lipotoxic and oxidative insults that lock endothelial enzymes into a permanent uncoupled state.
Protect kidney function. Both ADMA and SDMA rise as kidney filtration falls.
Do not expect ADMA, SDMA or IL-6 tests to guide decisions yet. Assays are not standardized, and ADMA explains only about 4 percent of the person-to-person variation in carotid wall thickness.
Context and Source
- Open Access Paper: Vascular aging biomarkers: the role of ADMA, SDMA, and inflammation
- Authors and Affiliations: Aleksandra Melnitskaia, Liubov Machekhina, Valentina Pykhtina, Alexey Churov, Olga Maltseva, Wu Zhenghi, Olga Tkacheva, and Irina Strazhesko; Russian Gerontological Research and Clinical Center, Moscow, Russia, and Department of Neurology, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University / Shenzhen Second People’s Hospital, Shenzhen, China.
- Journal Name: Frontiers in Cardiovascular Medicine
- Impact Evaluation: The impact score of this journal is 3.0 (CiteScore 6.1), evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.